Contains Mupirocin Calcium equivalent to 2% w/w mupirocin.
Pharmacology: Pharmacodynamics: Mupirocin is a topical antibacterial agent, active against those organisms responsible for the majority of skin infections eg, Staphylococcus aureus including methicillin-resistant strains, other staphylococci and streptococci. It is also active against gram-negative pathogens eg, Escherichia coli and Haemophilus influenzae.
Pharmacokinetics: Mupirocin penetrates intact human skin but the rate of systemic absorption appears to be low. Systemically absorbed mupirocin is rapidly metabolised to the inactive metabolite monic acid and quickly excreted by the kidneys.
Murozin Ointment is indicated for the treatment of bacterial skin infections eg, impetigo, folliculitis and furunculosis.
For external use only. Adults and Children: Apply to the affected area 3 times daily, for up to 10 days. The area may be covered with a dressing or occluded if desired. There is no long-term experience of mupirocin in humans.
Do not mix with other preparations, as there is a risk of dilution, resulting in a reduction in the antibacterial activity and potential loss of stability of the mupirocin.
The toxicity of mupirocin is very low. In the event of accidental ingestion or overdosage, symptomatic treatment should be given.
Murozin Ointment should not be given to patients with a history of hypersensitivity to mupirocin or any of the excipients.
Mupirocin is not suitable for ophthalmic or intranasal use. When used on the face, care should be taken to avoid the eyes. Should a possible sensitisation reaction or severe local irritation occur, treatment should be discontinued, the product should be washed off and appropriate alternative therapy for the infection instituted.
As with other antibacterial products, prolonged use may result in overgrowth of non-susceptible organisms.
Mupirocin has not been studied in infants under 1 year old and therefore it should not be used in these patients until further data become available.
Polyethylene glycol in the ointment can be absorbed from open wounds and damaged skin and is excreted by the kidneys. Should be used with caution if there is evidence of moderate or severe renal impairment.
Studies in experimental animals have shown mupirocin to be without teratogenic effects. However, there is inadequate evidence of safety to recommend the use during pregnancy. Adequate human and animal data on use during lactation are not available.
Adverse reactions are itching, erythema, stinging, burning and dryness localised to the area of application. Cutaneous sensitisation reactions and systemic allergic reactions have been reported rarely.
No drug interactions have been identified.
D06AX09 - mupirocin ; Belongs to the class of other topical antibiotics used in the treatment of dermatological diseases.